Stock listing

Lang & Schwarz:A41BDZ Crescent Biopharma, Inc. Aktie

German listing (Lang & Schwarz) of Crescent Biopharma, Inc. · home listing NASDAQ:CBIO

Follow Crescent Biopharma, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:CBIO

$13.00 USD +0.60 (+4.8%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:CBIO

Past year -0.6% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$12.53 – $13.30 USDNov 20, 2026
Volume
422,370 sharesNov 20, 2026
Market cap
$482.9M USDAt the close on Nov 20, 2026 · price × 37.14M shares outstanding
52-week range
$8.72 – $27.41 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$5.56M USDMedian day 264,400 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Crescent Biopharma, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:CBIO · Home$13.00 USD+0.60 (+4.8%)422,370$12.55$13.30$12.53$12.40Close on Nov 20, 2026
Frankfurt:C68€11.00 EUR+0.40 (+3.8%)—€11.00€11.00€11.00€10.60Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CBIO · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$13.00+0.60+4.8%$12.55$13.30$12.53422,370
$12.40-0.64-4.9%$13.07$13.62$12.29327,265
$13.04-0.46-3.4%$13.44$13.50$12.85214,585
$13.50-0.65-4.6%$14.09$14.42$12.95417,072
$14.15-0.22-1.5%$15.21$15.21$13.53284,754
$14.37-0.385-2.6%$14.51$15.44$14.16209,892
$14.76+0.835+6.0%$14.04$15.00$13.86269,517
$13.92+0.27+2.0%$13.51$14.05$13.27168,277
$13.65+0.11+0.8%$13.77$14.48$13.56206,110
$13.54+0.60+4.6%$12.84$13.91$12.78137,757
$12.94-0.88-6.4%$13.77$13.77$12.72191,582
$13.82+0.76+5.8%$13.43$14.01$13.17172,845
$13.06+0.15+1.2%$12.91$13.64$12.91159,531
$12.91-0.57-4.2%$13.75$13.92$12.68147,307
$13.48-0.59-4.2%$13.94$14.57$13.31189,518
$14.07+0.57+4.2%$13.66$14.94$13.56378,000
$13.50+0.23+1.7%$13.27$13.64$12.75238,700
$13.27+0.51+4.0%$12.81$13.47$12.56288,200
$12.76-0.06-0.5%$12.87$13.27$12.50210,600
$12.82-0.32-2.4%$13.36$13.36$12.62397,800
$13.14-0.03-0.2%$13.05$13.67$12.89164,100
$13.17+0.10+0.8%$13.16$13.81$13.12250,400
$13.07+0.71+5.7%$12.40$13.63$12.40299,600
$12.36+0.52+4.4%$11.91$12.94$11.82230,700
$11.84-0.64-5.1%$12.73$12.73$11.78208,200
$12.48-0.10-0.8%$12.62$13.19$12.31295,900
$12.58-0.33-2.6%$12.67$13.21$12.18284,800
$12.91-1.55-10.7%$14.46$14.67$12.85197,100
$14.46-0.45-3.0%$14.79$15.09$14.32153,900
$14.91+0.79+5.6%$14.07$15.28$14.07347,100
$14.12+0.63+4.7%$13.39$14.61$12.98301,200
$13.49-0.08-0.6%$13.47$14.20$13.271,049,300
$13.57-0.37-2.7%$14.78$14.93$13.46492,400
$13.94-0.38-2.7%$14.42$14.42$13.63187,000
$14.32+0.06+0.4%$14.48$14.55$14.07283,300
$14.26-0.33-2.3%$14.61$14.73$14.10300,900
$14.59-0.17-1.2%$14.89$15.00$14.23289,500
$14.76+0.23+1.6%$14.66$15.62$14.16684,600
$14.53+0.54+3.9%$13.93$14.76$13.50290,900
$13.99-0.25-1.8%$14.29$14.46$13.66228,700
$14.24+0.05+0.4%$14.04$14.48$13.44568,800
$14.19-2.25-13.7%$16.37$16.47$13.70727,700
$16.44+0.19+1.2%$16.48$16.65$16.01257,600
$16.25-0.64-3.8%$16.93$17.04$15.76375,800
$16.89+0.12+0.7%$16.67$17.87$16.153,123,500
$16.77-0.41-2.4%$17.60$18.57$16.32665,900
$17.18-1.62-8.6%$18.87$19.26$17.09528,900
$18.80-0.88-4.5%$19.60$20.31$18.40358,000
$19.68+0.27+1.4%$19.50$20.40$19.40251,200
$19.41-0.05-0.3%$19.81$20.35$19.11264,400
$19.46-0.53-2.7%$19.65$19.90$19.16233,100
$19.99-0.47-2.3%$20.30$20.91$19.92296,000
$20.46-0.42-2.0%$20.58$21.19$19.91646,700
$20.88+0.48+2.4%$20.09$21.53$20.09239,700
$20.40+1.86+10.0%$18.73$22.33$18.73773,300
$18.54+0.61+3.4%$18.00$19.01$17.93214,900
$17.93+1.33+8.0%$16.43$18.13$16.29788,100
$16.60-1.15-6.5%$17.65$17.65$16.14163,000
$17.75-0.01-0.1%$17.78$18.00$17.02149,100
$17.76-0.26-1.4%$17.89$18.26$17.5076,700
$18.02+1.02+6.0%$16.94$18.47$16.94317,600
$17.00+0.03+0.2%$17.12$17.66$16.87129,700
$16.97-0.18-1.0%$17.21$17.51$16.79131,500
$17.15+0.92+5.7%$16.39$17.19$16.03218,400
$16.23-1.09-6.3%$17.13$17.13$16.06124,800

Splits

1 split · NASDAQ:CBIO · every price before a split is adjusted for it

DayRatioWhat
1-for-100Consolidation
Ticker
Lang & Schwarz:A41BDZ
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Lang & Schwarz
Currency
EUR

What changed lately

Latest news

All Crescent Biopharma, Inc. news

Crescent Biopharma, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
21 in the last 12 months · 27 in all · newest Nov 12, 2026 · oldest 2025
Calls
13 calls with a replay · 13 with a transcript · latest May 9, 2024
Decks
7 decks · latest October 2026

Where Crescent Biopharma, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:CBIO · Home listingNASDAQUnited StatesUSD
Lang & Schwarz:A41BDZ · This pageLang & SchwarzGermanyEUR
BOATS:CBIOBOATSUnited StatesUSD
Frankfurt:C68FrankfurtGermanyEUR
gettex:C68gettexGermanyEUR

Valuation

EV/sales 13.1× against a median of 12.5×: 3rd lowest of 5 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$196.0M USD
P/E
Loss
EV/sales
13.1×
EV/EBITDA
Negative EBITDA
Price/book
1.8×
Gross margin
Revenue too small
Operating margin
Revenue too small
Net margin
−727.6%
Debt to equity
0.0×
Beta vs S&P 500
0.92

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Crescent Biopharma, Inc. · NASDAQ:CBIOUS$482.9MUS$196.0Mn/a13.1×n/a1.8×−727.6%0.0×0.92
Wave Life Sciences Ltd. · NASDAQ:WVEUS$504.9MUS$74.16Mn/a1.1×n/a1.3×−296.9%0.0×1.70
Adlai Nortye Group Ltd. · NASDAQ:ANLUS$502.2MUS$297.0Mn/a59.4×n/a2.3×−710.6%0.1×1.96
Steminent Biotherapeutics, Inc. · TPEX:7729US$496.9MUS$470.4Mn/an/an/a16.2×n/a0.0×n/a
Xuanzhu Biopharmaceutical Co., Ltd. Class H · HKEX:2575US$495.2MUS$407.1Mn/a23.2×n/a2.2×−200.8%0.0×n/a
TenNor Therapeutics Suzhou Ltd. Class H · HKEX:6872US$489.2MUS$391.6Mn/an/an/a5.0×n/a0.1×n/a
Sana Biotechnology, Inc. · NASDAQ:SANAUS$476.4MUS$408.5Mn/an/an/a2.6×n/a0.3×2.29
Regenxbio Inc. · NASDAQ:RGNXUS$473.4MUS$289.0Mn/a1.9×n/a3.2×−113.9%0.5×1.60
Monopar Therapeutics Inc. · NASDAQ:MNPRUS$467.6MUS$362.8Mn/an/an/a3.7×n/a0.0×1.18
BlossomHill Therapeutics, Inc. · NASDAQ:BLSMUS$461.2MUS$259.4Mn/an/an/a2.2×n/a0.1×n/a
Neurogene Inc. · NASDAQ:NGNEUS$458.5MUS$106.4Mn/an/an/a1.3×n/a0.0×1.47
Median of the othersUS$482.8MUS$329.9M12.5×2.5×−248.8%0.1×1.65

Forecasts

7 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
31.50 USD · Analysts' mean
EPS, year to Dec 2026
-2.35 · 3 analysts
Revenue, year to Dec 2026
1.73M · 7 analysts

Team and board

Officers

OfficerRole
Joshua BrummChief Executive Officer
Rick ScalzoChief Financial Officer
Ryan LynchSenior Vice President, Finance and Chief Accounting Officer
Jonathan McNeillPresident and Chief Operating Officer
Barbara BisphamGeneral Counsel
Jenna PoistDirector, Corporate Communications
Tanya SenguptaExecutive Vice President, Chief of Strategy and Operations
Wenjie ChengSenior Vice President, Technical Operations
Amy ReillyChief Communications Officer
Chris DoughtyChief Business Officer
Ellie ImChief Medical Officer
Jan PinkasChief Scientific Officer

Board

DirectorRole
Peter HarwinChair of Board
David LubnerDirector
Jonathan ViolinDirector
Joshua BrummChief Executive Officer
Susan MoranDirector

Events

Calls

CallWhenStatus
GlycoMimetics, Inc. (GLYC) Q1 2024 Earnings CallThu, May 09, 2024 · 8:30 AM ETReplay
GlycoMimetics, Inc. (GLYC) Q4 2023 Earnings CallWed, Mar 27, 2024 · 8:30 AM ETReplay
GlycoMimetics, Inc. (GLYC) Q3 2023 Earnings CallFri, Nov 03, 2023 · 8:30 AM ETReplay
GlycoMimetics, Inc. (GLYC) Q2 2023 Earnings CallWed, Aug 02, 2023 · 8:30 AM ETReplay
GlycoMimetics, Inc. (GLYC) Q1 2023 Earnings CallWed, May 03, 2023 · 8:30 AM ETReplay
GlycoMimetics, Inc. (GLYC) Q4 2022 Earnings CallWed, Mar 29, 2023 · 8:30 AM ETReplay
GlycoMimetics, Inc. (GLYC) Q3 2022 Earnings CallWed, Nov 09, 2022 · 8:30 AM ETReplay
GlycoMimetics, Inc. (GLYC) Q2 2022 Earnings CallWed, Aug 03, 2022 · 8:30 AM ETReplay
GlycoMimetics, Inc. (GLYC) Q1 2022 Earnings CallThu, Apr 28, 2022 · 8:30 AM ETReplay
GlycoMimetics, Inc. (GLYC) Q4 2021 Earnings CallThu, Mar 03, 2022 · 8:30 AM ETReplay
All 13 calls
CallWhenStatus
GlycoMimetics, Inc. (GLYC) Q3 2021 Earnings CallTue, Nov 02, 2021 · 8:30 AM ETReplay
GlycoMimetics, Inc. (GLYC) Q2 2021 Earnings CallThu, Aug 05, 2021 · 8:30 AM ETReplay
GlycoMimetics, Inc. (GLYC) Q1 2021 Earnings CallMon, May 03, 2021 · 8:30 AM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 12, 2026 · After close−1.5%
Q2 2026Jul 30, 2026 · Before open+1.7%
Q1 2026Apr 30, 2026−13.7%
Q4 2025Feb 26, 2026 · Before open−1.1%
Q3 2025Nov 6, 2025 · Before open+5.4%
Q2 2025Jul 31, 2025 · Before open−1.4%
Q1 2025Jun 18, 2025 · After close+2.6%
Q4 2024Feb 27, 2025−3.6%
Q3 2024Nov 29, 2024+6.5%
Q2 2024Aug 1, 2024−9.1%
All 20 quarters
QuarterResultsShare move
Q1 2024May 10, 2024−13.3%
Q4 2023Mar 27, 2024+5.3%
Q3 2023Nov 3, 2023+3.1%
Q2 2023Aug 2, 2023−1.8%
Q1 2023May 3, 2023+3.5%
Q4 2022Mar 29, 2023−10.7%
Q3 2022Nov 9, 2022+42.0%
Q2 2022Aug 3, 2022+10.4%
Q1 2022Apr 28, 2022−14.3%
Q4 2021Mar 3, 2022−21.3%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (October 2026)Investor deck56 slidesOctober 2026
Investor Presentation (December 2025)Investor deck53 slidesDec 4, 2025
Glycomimetics — Merger or Acquisition (April 2025)Merger or acquisition27 slidesApr 3, 2025
Glycomimetics — Merger or Acquisition (February 2025)Merger or acquisition27 slidesFeb 28, 2025
Glycomimetics — Merger or Acquisition (January 2025)Merger or acquisition27 slidesJan 13, 2025
Investor Presentation (November 2024)Investor deck26 slidesNov 18, 2024
Investor Presentation (November 2024)Investor deck25 slidesNovember 2024

Open Decks

Financings

RaiseDate
Public offering of ordinary shares and pre-funded warrants
Closed: US$143.7M in the latest tranche · US$14.5 a share · Jefferies +4
Dealers: Jefferies (co-lead), TD Cowen (co-lead), Guggenheim Securities (co-lead), Cantor (co-lead), LifeSci Capital
Jul 30, 2026
Private placement of ordinary shares and pre-funded warrants
Announced: about US$185M · US$13.41 a share · Jefferies +5
Dealers: Jefferies, TD Cowen, Guggenheim Securities, Cantor, Wedbush & Co., Piper Sandler
Buyers: Forbion; Fairmount; Vestal Point Capital; BVF Partners; ADAR1; Balyasny Asset Management; Venrock Healthcare Capital Partners
Use of proceeds: Advance preclinical and clinical development of product candidates, working capital and general corporate purposes
Dec 4, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Went public as GLYCOMIMETICS INC. Priced at US$8.00 a share on Jan 9, 2014.

Price
US$8.00 a share
Shares offered
7,000,000 shares of common stock
Offering size
US$56 million
Underwriters' option
Up to 1,050,000 more shares
Underwriters
Jefferies, Barclays, Stifel, Canaccord Genuity · In the order on the cover

Steps

StepWhen
Draft sent to the SEC in confidenceAug 21, 2013
Filed publiclyOct 4, 2013
Amended 4 timesNewest Jan 7, 2014
Shares registered with an exchangeNov 5, 2013
Declared effective by the SECJan 9, 2014
Final prospectus, with the priceJan 10, 2014

Open IPO · From the cover of the final prospectus (424B4) filed Jan 10, 2014

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue10.8M10.0K75.0K1.16M10.2M18.5K
Cost of revenue84.0K35.2K153.3K1.03M951.6K899.3K275.1K263.5K
Gross profit10.8M-35.2K10.0K75.0K1.16M10.2M-899.3K-275.1K-263.5K18.5K
Research and development138.1M14.3M20.1M28.4M47.5M44.9M47.0M40.1M24.1M23.3M
Selling, general and administrative25.4M16.3M19.2M19.1M17.1M16.7M14.4M11.4M9.83M8.65M
Operating income-152.6M-40.0M-39.3M-47.4M-63.4M-51.5M-61.4M-51.5M-33.9M-31.9M
Depreciation and amortization84.0K35.2K153.3K207.1K264.6K270.8K279.2K275.1K263.5K190.5K
EBITDA-152.5M-40.0M-39.1M-47.2M-63.2M-51.2M-61.1M-51.2M-33.7M-31.7M
Interest expense2.19M852.0K
Income before tax-151.9M-48.5M-36.9M-46.7M-63.4M-51.0M-57.9M-48.3M-33.3M-31.8M
Income tax2.00M-3.78M3.23M
Net income-153.9M-37.9M-36.9M-46.7M-63.4M-51.0M-57.9M-48.3M-33.3M-31.8M
Earnings per share, basic-5.59-0.59-0.58-0.89-1.23-1.12-1.34-1.18-1.13-1.50
Earnings per share, diluted-0.59-0.58-0.89-1.23-1.12-1.34-1.18-1.13-1.50

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents213.2M34.8M41.8M47.9M90.3M137.0M158.2M209.9M123.9M40.0M
Short-term investments10.6K
Receivables18.0M0175.8K144.0K1.35K2.15K186.0K413.1K102.0K268.7K
Inventory-405198.8K
Current assets236.7M34.8M43.8M50.7M90.8M138.3M162.5M212.3M127.2M40.5M
Property, plant and equipment846.0K0242.4K368.8K620.7K822.9K957.2K1.11M1.06M
Total assets240.3M35.6M45.3M51.8M94.3M142.8M168.0M214.8M128.6M42.4M
Accounts payable10.00M329.3K868.1K970.2K2.11M2.09M1.44M2.66M2.65M1.57M
Current liabilities36.1M9.61M6.84M8.88M11.8M12.4M11.0M8.76M8.17M6.33M
Long-term debt37.5M
Total debt1.64M37.5M808.4K918.6K1.92M2.82M3.62M
Total liabilities37.3M47.1M6.90M8.88M12.7M14.6M13.8M9.37M8.88M7.09M
Shareholders' equity203.0M-15.5M38.4M42.9M81.6M128.2M154.2M205.5M119.7M35.3M
Shares outstanding27.6M1.02M64.4M54.4M52.3M49.0M43.5M43.2M34.4M23.3M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-71.5M-31.1M-34.9M-46.5M-57.5M-39.2M-52.0M-43.3M-29.8M-29.7M
Capital spending-919.0K-9.97K-21.4K-84.2K-14.9K-68.5K-144.9K-125.6K-294.1K-704.2K
Free cash flow-72.5M-31.1M-34.9M-46.5M-57.5M-39.3M-52.1M-43.5M-30.1M-30.4M
Cash from investing-72.9M20.0K-21.4K-84.2K-14.9K-68.5K-144.9K-125.6K-294.1K-704.2K
Cash from financing323.0M5.40K28.8M4.16M10.7M18.1M412.9K129.4M113.9M23.7M
Share buybacks-177.0K
Change in cash178.5M-31.1M-6.08M-42.4M-46.8M-21.2M-51.7M86.0M83.9M-6.76M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
8-K · Current reportNov 12, 2026ResultsSEC
10-Q · Quarterly reportNov 12, 2026Quarterly reportSEC
SCHEDULE 13G · Big-stake noticeOct 27, 2026Big-stake noticeSEC
8-K · Current reportOct 15, 2026Current reportSEC
4 · Change in ownershipSep 18, 2026Insider tradeSEC
4 · Change in ownershipSep 18, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipSep 18, 2026Insider tradeSEC
4 · Change in ownershipSep 18, 2026Insider tradeSEC
4 · Change in ownershipSep 18, 2026Insider tradeSEC
4 · Change in ownershipSep 18, 2026Insider tradeSEC
4 · Change in ownershipSep 18, 2026Insider tradeSEC
S-8 · Registration statement for employee plansSep 18, 2026Offer documentSEC
144 · Notice of proposed saleSep 17, 2026Other filingsSEC
144 · Notice of proposed saleSep 17, 2026Other filingsSEC
144 · Notice of proposed saleSep 16, 2026Other filingsSEC
144 · Notice of proposed saleSep 16, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveAug 3, 2026Other filingsSEC
POS AM · Amendment to an effective registrationJul 30, 2026Offer documentSEC
424B3 · ProspectusJul 30, 2026Offer documentSEC
10-Q · Quarterly reportJul 30, 2026Quarterly reportSEC
8-K · Current reportJul 30, 2026ResultsSEC
SCHEDULE 13D/A · Big-stake notice, amendedJul 20, 2026Big-stake noticeSEC
4 · Change in ownershipJul 20, 2026Insider tradeSEC
8-K · Current reportJul 15, 2026Current reportSEC
424B5 · ProspectusJul 15, 2026Offer documentSEC
8-K · Current reportJul 14, 2026ResultsSEC
424B5 · ProspectusJul 14, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveJul 13, 2026Other filingsSEC
S-3 · Registration statementJul 1, 2026Offer documentSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
424B3 · ProspectusJun 22, 2026Offer documentSEC
10-Q/A · Quarterly report, amendedJun 22, 2026Quarterly reportSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
8-K · Current reportJun 3, 2026Meeting outcomeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2026Big-stake noticeSEC
424B3 · ProspectusApr 29, 2026Offer documentSEC
8-K · Current reportApr 29, 2026ResultsSEC
10-Q · Quarterly reportApr 29, 2026Quarterly reportSEC
DEFA14A · Additional proxy materialApr 21, 2026Meeting noticeSEC
DEFA14A · Additional proxy materialApr 21, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 21, 2026Meeting noticeSEC
424B3 · ProspectusMar 17, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveMar 4, 2026Other filingsSEC
POS AM · Amendment to an effective registrationMar 2, 2026Offer documentSEC
424B3 · ProspectusFeb 26, 2026Offer documentSEC
S-8 · Registration statement for employee plansFeb 26, 2026Offer documentSEC
8-K · Current reportFeb 26, 2026ResultsSEC
10-K · Annual reportFeb 26, 2026Annual reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 5, 2026Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveJan 16, 2026Other filingsSEC
424B3 · ProspectusJan 15, 2026Offer documentSEC
CORRESP · Letter to the SECJan 13, 2026Other filingsSEC
UPLOAD · Letter from the SECJan 12, 2026Other filingsSEC
S-1 · Registration statementJan 7, 2026Offer documentSEC
4 · Change in ownershipDec 17, 2025Insider tradeSEC
4 · Change in ownershipDec 17, 2025Insider tradeSEC
4 · Change in ownershipDec 17, 2025Insider tradeSEC
4 · Change in ownershipDec 17, 2025Insider tradeSEC
4 · Change in ownershipDec 17, 2025Insider tradeSEC
4 · Change in ownershipDec 17, 2025Insider tradeSEC
4 · Change in ownershipDec 17, 2025Insider tradeSEC
4 · Change in ownershipDec 17, 2025Insider tradeSEC
S-4 POSDec 12, 2025Other filingsSEC
SCHEDULE 13G · Big-stake noticeDec 11, 2025Big-stake noticeSEC
4 · Change in ownershipDec 10, 2025Insider tradeSEC
4 · Change in ownershipDec 10, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedDec 8, 2025Big-stake noticeSEC
4 · Change in ownershipDec 8, 2025Insider tradeSEC
8-K · Current reportDec 4, 2025Material contractSEC
S-8 · Registration statement for employee plansNov 6, 2025Offer documentSEC
8-A12B/A · Registration of shares for listing on an exchange, amendedNov 6, 2025Other filingsSEC
10-Q · Quarterly reportNov 6, 2025Quarterly reportSEC
8-K · Current reportNov 6, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 14, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeOct 9, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 20, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
8-K · Current reportJul 31, 2025ResultsSEC
10-Q · Quarterly reportJul 31, 2025Quarterly reportSEC
4 · Change in ownershipJul 16, 2025Insider tradeSEC
3 · Initial statement of ownershipJul 15, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeJul 8, 2025Big-stake noticeSEC
3 · Initial statement of ownershipJun 30, 2025Insider tradeSEC
3 · Initial statement of ownershipJun 30, 2025Insider tradeSEC
4 · Change in ownershipJun 23, 2025Insider tradeSEC
4 · Change in ownershipJun 23, 2025Insider tradeSEC
4 · Change in ownershipJun 23, 2025Insider tradeSEC
4 · Change in ownershipJun 23, 2025Insider tradeSEC
4 · Change in ownershipJun 23, 2025Insider tradeSEC
SCHEDULE 13D · Big-stake noticeJun 23, 2025Big-stake noticeSEC
3 · Initial statement of ownershipJun 23, 2025Insider tradeSEC
3 · Initial statement of ownershipJun 23, 2025Insider tradeSEC
3 · Initial statement of ownershipJun 23, 2025Insider tradeSEC
3 · Initial statement of ownershipJun 23, 2025Insider tradeSEC
3 · Initial statement of ownershipJun 23, 2025Insider tradeSEC
3 · Initial statement of ownershipJun 23, 2025Insider tradeSEC
3 · Initial statement of ownershipJun 23, 2025Insider tradeSEC
3 · Initial statement of ownershipJun 23, 2025Insider tradeSEC
3 · Initial statement of ownershipJun 23, 2025Insider tradeSEC
3 · Initial statement of ownershipJun 23, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeJun 23, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJun 20, 2025Big-stake noticeSEC
8-K · Current reportJun 18, 2025ResultsSEC
4 · Change in ownershipJun 17, 2025Insider tradeSEC
8-K · Current reportJun 6, 2025Meeting outcomeSEC
425May 30, 2025Other filingsSEC
8-K · Current reportMay 30, 2025Current reportSEC
425May 29, 2025Other filingsSEC
SEC STAFF LETTERMay 16, 2025Other filingsSEC
EFFECT · Notice that a registration is effectiveMay 15, 2025Other filingsSEC
10-Q · Quarterly reportMay 14, 2025Quarterly reportSEC
424B3 · ProspectusMay 14, 2025Offer documentSEC
CORRESP · Letter to the SECMay 13, 2025Other filingsSEC
CORRESP · Letter to the SECMay 12, 2025Other filingsSEC
S-4/A · Registration statement, amendedMay 12, 2025Offer documentSEC
UPLOAD · Letter from the SECMay 8, 2025Other filingsSEC
CORRESP · Letter to the SECApr 28, 2025Other filingsSEC
S-4/A · Registration statement, amendedApr 28, 2025Offer documentSEC
425Apr 28, 2025Other filingsSEC
8-K · Current reportApr 28, 2025Material contractSEC
425Apr 28, 2025Other filingsSEC
UPLOAD · Letter from the SECApr 22, 2025Other filingsSEC
CORRESP · Letter to the SECApr 4, 2025Other filingsSEC
CORRESP · Letter to the SECApr 4, 2025Other filingsSEC
S-4/A · Registration statement, amendedApr 4, 2025Offer documentSEC
425Apr 3, 2025Other filingsSEC
425Apr 3, 2025Other filingsSEC
SEC STAFF LETTERMar 27, 2025Other filingsSEC
UPLOAD · Letter from the SECMar 17, 2025Other filingsSEC
425Feb 28, 2025Other filingsSEC
425Feb 27, 2025Other filingsSEC
425Feb 25, 2025Other filingsSEC
8-K · Current reportFeb 25, 2025Management or board changeSEC
S-4 · Registration statementFeb 18, 2025Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
425Feb 14, 2025Other filingsSEC
8-K · Current reportFeb 14, 2025Material contractSEC
10-K · Annual reportFeb 13, 2025Annual reportSEC
8-K · Current reportJan 31, 2025Management or board changeSEC
DEFA14A · Additional proxy materialJan 13, 2025Meeting noticeSEC
8-K · Current reportJan 13, 2025Current reportSEC
8-K · Current reportDec 26, 2024Current reportSEC
SC 13G · Big-stake noticeNov 27, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 13, 2024Quarterly reportSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
DEFA14A · Additional proxy materialNov 7, 2024Meeting noticeSEC
8-K · Current reportNov 7, 2024Current reportSEC
SC 13G · Big-stake noticeNov 6, 2024Big-stake noticeSEC
SC 13D · Big-stake noticeNov 4, 2024Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 4, 2024Big-stake noticeSEC
DEFA14A · Additional proxy materialOct 29, 2024Meeting noticeSEC
8-K · Current reportOct 29, 2024Material contractSEC
SC 13G/A · Big-stake notice, amendedAug 15, 2024Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2024Big-stake noticeSEC
4 · Change in ownershipAug 9, 2024Insider tradeSEC
10-Q · Quarterly reportAug 8, 2024Quarterly reportSEC
4 · Change in ownershipAug 7, 2024Insider tradeSEC
4 · Change in ownershipAug 5, 2024Insider tradeSEC
4 · Change in ownershipJul 30, 2024Insider tradeSEC
8-K · Current reportJul 30, 2024Management or board changeSEC
SC 13G/A · Big-stake notice, amendedJul 29, 2024Big-stake noticeSEC
3 · Initial statement of ownershipJul 29, 2024Insider tradeSEC
8-K · Current reportJun 26, 2024Current reportSEC
4 · Change in ownershipJun 24, 2024Insider tradeSEC
4 · Change in ownershipJun 20, 2024Insider tradeSEC
8-K · Current reportJun 13, 2024Management or board changeSEC
8-K · Current reportJun 4, 2024Current reportSEC
10-Q · Quarterly reportMay 9, 2024Quarterly reportSEC
SC 13D/A · Big-stake notice, amendedMay 8, 2024Big-stake noticeSEC
8-K · Current reportMay 6, 2024ResultsSEC
8-K · Current reportMay 2, 2024Meeting outcomeSEC
4 · Change in ownershipMay 1, 2024Insider tradeSEC
4 · Change in ownershipMay 1, 2024Insider tradeSEC
4 · Change in ownershipMay 1, 2024Insider tradeSEC
4 · Change in ownershipMay 1, 2024Insider tradeSEC
4 · Change in ownershipMay 1, 2024Insider tradeSEC
4 · Change in ownershipMay 1, 2024Insider tradeSEC
4 · Change in ownershipMay 1, 2024Insider tradeSEC
4 · Change in ownershipApr 2, 2024Insider tradeSEC
4 · Change in ownershipApr 2, 2024Insider tradeSEC
4 · Change in ownershipApr 2, 2024Insider tradeSEC

This page holds 200 of 682 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Crescent Biopharma, Inc.’s releases · as of Sep 30, 2026

Common shares
37,143,940
Fully diluted
37,143,940

Fully diluted

LineShares
Common shares37,143,940

Share count over time

CountShares
Nov 22, 202637,143,940

Open Cap table

Shareholders

Institutions

HolderSharesValueAs of
Fidelity5.9MUS$86.2MSep 30, 2026
Fairmount Funds Management LLC3.6MUS$52.5MSep 30, 2026
Bvf Inc3.09MUS$45.1MSep 30, 2026
Vestal Point Capital, LP3MUS$43.8MSep 30, 2026
BlackRock2.14MUS$31.2MSep 30, 2026
Venrock Adviser, LLC2.13MUS$31.1MSep 30, 2026
Fcpm III Services B.V.2.02MUS$29.5MSep 30, 2026
Vanguard1.79MUS$26.1MSep 30, 2026
Opaleye Management Inc.1.65MUS$24MSep 30, 2026
Balyasny Asset Management L.P.1.61MUS$23.5MSep 30, 2026
Show 50 holders
HolderSharesValueAs of
Tang Capital Management LLC1.16MUS$16.9MSep 30, 2026
Jennison Associates LLC1.1MUS$16.1MSep 30, 2026
Blackstone Inc.1.06MUS$15.5MSep 30, 2026
Logos Global Management LP850KUS$12.4MSep 30, 2026
State Street843KUS$12.3MSep 30, 2026
Geode Capital735KUS$10.7MSep 30, 2026
Perceptive Advisors LLC707KUS$10.3MSep 30, 2026
Ameriprise681KUS$9.93MSep 30, 2026
Adage Capital Partners Gp, L.L.C.500KUS$7.29MSep 30, 2026
Siren, L.L.C.400KUS$5.84MSep 30, 2026
Rtw Investments, LP373KUS$5.44MSep 30, 2026
NEXTBio Capital Management LP373KUS$5.44MSep 30, 2026
Remedium Capital Partners, LLC361KUS$5.27MSep 30, 2026
Squadron Capital Management LLC350KUS$5.11MSep 30, 2026
Citadel350KUS$5.1MSep 30, 2026
Sphera Funds Management LTD.280KUS$4.08MSep 30, 2026
Woodline Partners LP270KUS$3.93MSep 30, 2026
ADAR1 Capital Management, LLC231KUS$3.38MSep 30, 2026
Northern Trust230KUS$3.36MSep 30, 2026
Goldman Sachs227KUS$3.32MSep 30, 2026
Two Sigma211KUS$3.08MSep 30, 2026
UBS207KUS$3.01MSep 30, 2026
Sectoral Asset Management Inc168KUS$2.45MSep 30, 2026
Ikarian Capital, LLC150KUS$2.19MSep 30, 2026
Nuveen145KUS$2.11MSep 30, 2026
Marshall Wace, LLP131KUS$1.92MSep 30, 2026
Seven Grand Managers, LLC100KUS$1.46MSep 30, 2026
Schwab93,663US$1.37MSep 30, 2026
Bank of America90,646US$1.32MSep 30, 2026
Millennium84,896US$1.24MSep 30, 2026
XTX Topco Ltd80,064US$1.17MSep 30, 2026
Algert Global LLC75,957US$1.11MSep 30, 2026
Burkehill Global Management, LP74,000US$1.08MSep 30, 2026
Wellington73,086US$1.07MSep 30, 2026
BNY67,826US$990KSep 30, 2026
Susquehanna55,725US$813KSep 30, 2026
Boothbay Fund Management, LLC42,794US$624KSep 30, 2026
Quadrature Capital Ltd41,175US$601KSep 30, 2026
Schonfeld Strategic Advisors LLC32,349US$472KSep 30, 2026
T. Rowe Price32,326US$472KSep 30, 2026

This page holds 50 of 101 holders. Open Shareholders

Funds

HolderSharesValueAs of
Vanguard Total Stock Market Index Fund662KUS$11.9MJun 30, 2026
iShares Russell 2000 ETF517KUS$9.3MJun 30, 2026
Fidelity Small Cap Growth Fund432KUS$6.26MJul 31, 2026
Fidelity Advisor Biotechnology Fund356KUS$5.15MJul 31, 2026
Fidelity Growth Company Fund293KUS$6.04MMay 31, 2026
Fidelity Small Cap Index Fund236KUS$3.42MJul 31, 2026
Fidelity Small Cap Growth K6 Fund221KUS$3.2MJul 31, 2026
iShares Russell 2000 Growth ETF199KUS$3.59MJun 30, 2026
T. Rowe Price Health Sciences Fund, Inc.188KUS$3.38MJun 30, 2026
Fidelity Advisor Health Care Fund149KUS$2.16MJul 31, 2026
Show 50 holders
HolderSharesValueAs of
Select Biotechnology Portfolio113KUS$2.34MMay 31, 2026
Fidelity Growth Company K6 Fund103KUS$2.13MMay 31, 2026
Vanguard Extended Market Index Fund83,801US$1.51MJun 30, 2026
iShares Micro-Cap ETF71,187US$1.28MJun 30, 2026
Fidelity Series Growth Company Fund69,195US$1.43MMay 31, 2026
Fidelity Small Cap Stock Fund65,700US$951KJul 31, 2026
Schwab Small-Cap Index Fund52,768US$764KJul 31, 2026
Master Small Cap Index Series39,685US$714KJun 30, 2026
Fidelity Extended Market Index Fund38,989US$805KMay 31, 2026
Nuveen Small Cap Blend Index Fund28,660US$415KJul 31, 2026
EQ/2000 Managed Volatility Portfolio22,637US$407KJun 30, 2026
Fidelity Small Cap Growth Index Fund20,234US$364KJun 30, 2026
Nuveen Equity Index Fund18,969US$274KJul 31, 2026
T. Rowe Price Health Sciences Portfolio17,631US$317KJun 30, 2026
Fidelity Nasdaq Composite Index Fund17,565US$363KMay 31, 2026
Virtus Biotech Clinical Trials Etf17,344US$251KJul 31, 2026
LVIP State Street Small-Cap Index Fund15,700US$283KJun 30, 2026
Avantis U.S. Small Cap Equity ETF15,612US$322KMay 31, 2026
Fidelity Total Market Index Fund12,699US$262KMay 31, 2026
Vanguard Balanced Index Fund11,212US$202KJun 30, 2026
Fidelity Series Total Market Index Fund11,053US$228KMay 31, 2026
Vanguard Institutional Total Stock Market Index Fund10,796US$194KJun 30, 2026
Global X Russell 2000 ETF10,277US$149KJul 31, 2026
Small Cap Index Fund10,253US$185KJun 30, 2026
T. Rowe Price Extended Equity Market Index Fund8,300US$149KJun 30, 2026
State Street Small/Mid Cap Equity Index Portfolio7,600US$137KJun 30, 2026
MetLife Russell 2000 Index Portfolio7,246US$130KJun 30, 2026
ATM Small Cap Managed Volatility Portfolio7,084US$128KJun 30, 2026
Small-Cap Index Portfolio6,023US$108KJun 30, 2026
Health Sciences Trust5,959US$107KJun 30, 2026
Goldman Sachs Absolute Return Tracker Fund5,460US$98,280Jun 30, 2026
1290 VT Micro Cap Portfolio4,778US$86,004Jun 30, 2026
NVIT Small Cap Index Fund4,633US$83,394Jun 30, 2026
Small Cap Index Trust4,483US$80,694Jun 30, 2026
EQ/T.Rowe Price Health Sciences Portfolio4,414US$79,452Jun 30, 2026
iShares Russell Small/Mid-Cap Index Fund3,763US$54,451Jul 31, 2026
DWS Small Cap Index VIP3,396US$61,128Jun 30, 2026
T. Rowe Price Small-Cap Index Fund3,294US$59,292Jun 30, 2026
EQ/Morgan Stanley Small Cap Growth Portfolio3,209US$57,762Jun 30, 2026
BlackRock Small Cap Index V.I. Fund2,837US$51,066Jun 30, 2026

This page holds 50 of 80 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
McNeill Jonathan
Officer: President and COO
Sale3,839USD 16.71US$64,150Sep 18, 2026
Brumm Joshua T
Director, Officer: Chief Executive Officer
Sale7,837USD 16.71US$131KSep 18, 2026
McNeill Jonathan
Officer: President and COO
Sale731USD 17.90US$13,085Sep 16, 2026
Brumm Joshua T
Director, Officer: Chief Executive Officer
Sale1,610USD 17.90US$28,819Sep 16, 2026
Bispham Barbara Harlin
Officer: See Remarks
Sale620USD 17.90US$11,098Sep 16, 2026
Scalzo Richard William
Officer: Chief Financial Officer
Sale568USD 17.90US$10,167Sep 16, 2026
Im Ellie Eunkyung
Officer: Chief Medical Officer
Sale623USD 17.90US$11,152Sep 16, 2026
Pinkas Jan
Officer: Chief Scientific Officer
Sale658USD 17.90US$11,778Sep 16, 2026
Lynch Ryan
Officer: See Remarks
Sale240USD 17.90US$4,296Sep 16, 2026
Fairmount Healthcare Fund II L.P.
Director, 10% owner
Buy853,450USD 14.50US$12.4MJul 16, 2026
All 17 trades
TradeTradeSharesPriceValueDate
Brumm Joshua T
Director, Officer: Chief Executive Officer
Sale42,305USD 17.99US$761KJun 22, 2026
McNeill Jonathan
Officer: President and COO
Sale20,549USD 17.99US$370KJun 22, 2026
Im Ellie Eunkyung
Officer: Chief Medical Officer
Sale1,219USD 17.99US$21,930Jun 22, 2026
Bispham Barbara Harlin
Officer: See Remarks
Sale1,218USD 17.99US$21,912Jun 22, 2026
Scalzo Richard William
Officer: Chief Financial Officer
Sale1,112USD 17.99US$20,005Jun 22, 2026
Pinkas Jan
Officer: Chief Scientific Officer
Sale1,288USD 17.99US$23,171Jun 22, 2026
Lynch Ryan
Officer: See Remarks
Sale465USD 17.99US$8,365Jun 22, 2026

Big stakes

StakeStakeSharesDateFiling
Peter Harwin16.52%6.6MJul 16, 2026Schedule 13D
FMR LLC15.00%4.13MDec 31, 2025Schedule 13G
BVF PARTNERS L P/IL9.80%3.69MSep 30, 2026Schedule 13G
Vestal Point Capital, LP8.10%3MSep 30, 2026Schedule 13G
ForGrowth III PA B.V.6.10%1.68MDec 8, 2025Schedule 13G
Venrock Healthcare Capital Partners III, L.P.5.90%2.23MSep 30, 2026Schedule 13G
BlackRock, Inc.5.60%2.08MSep 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
M James Barrett
Other companies: Senseonics Holdings, Inc. (Director · Mar 17, 2016 – May 30, 2019 · Past); Kineta Inc. (Director · Feb 10, 2016 – Jun 15, 2018 · Past); Zosano Pharma Corp (Director · Jan 26, 2015 – Jan 30, 2015 · Past); Loxo Oncology Inc (Director · Jul 31, 2014 – Jul 28, 2015 · Past); Roka Bioscience Inc (Director · Jul 16, 2014 – Jun 28, 2017 · Past); Omthera Pharmaceuticals Inc (Director · Jul 18, 2013 – Jul 18, 2013 · Past); Supernus Pharmaceuticals, Inc. (Director · Apr 30, 2012 – Mar 16, 2016 · Past); Clovis Oncology Inc (Director · Nov 15, 2011 – Oct 11, 2018 · Past); Amicus Therapeutics Inc (Director · Jun 15, 2010 – Jun 12, 2014 · Past); Medimmune Inc (Director · Jun 30, 2006 – Jun 18, 2007 · Past); Pharmion Corp (Director · Jun 8, 2006 – Mar 7, 2008 · Past); Gyre Therapeutics, Inc. (Director · Apr 11, 2006 – Jun 7, 2012 · Past); Inhibitex Inc (Director · Feb 1, 2006 – Feb 13, 2012 · Past); Iomai Corp (Director · Jan 25, 2006 – Aug 4, 2008 · Past)
Director · Jan 9, 2014 – May 18, 2018 · Past
David Lubner
Other companies: Braveheart Bio, Inc. (Director · Since at least Aug 5, 2026); CARGO Therapeutics, Inc. (Director · Since at least Nov 9, 2023); Arcellx Inc (Director · Since at least Feb 3, 2022); Dyne Therapeutics, Inc. (Board Member · Since at least Jul 31, 2020); Disc Medicine, Inc. (Director · Feb 5, 2021 – Oct 4, 2021 · Past); Vor Biopharma Inc. (Director · Feb 4, 2021 – May 22, 2025 · Past); POINT Biopharma Global Inc (Director · Jul 7, 2020 – Dec 26, 2023 · Past); Nightstar Therapeutics PLC (Director · Jan 1, 2019 – Jun 7, 2019 · Past); Ra Pharmaceuticals Inc (Executive VP and CFO · Oct 25, 2016 – Apr 2, 2020 · Past); Tetraphase Pharmaceuticals Inc (SVP and CFO · Mar 19, 2013 – Aug 14, 2015 · Past)
Director · Since at least Jun 13, 2025
Peter Harwin
Other companies: Damora Therapeutics, Inc. (Chairman of the Board · Since at least Nov 10, 2025); Jade Biosciences, Inc. (Director · Since at least Apr 28, 2025); Zenas BioPharma, Inc. (Director · Since at least Sep 12, 2024); Oruka Therapeutics, Inc. (Director · Since at least Aug 29, 2024); Apogee Therapeutics, Inc. (Director · Since at least Jul 13, 2023); Spyre Therapeutics, Inc. (Director · Since at least Jun 22, 2023); Cogent Biosciences, Inc. (Founding Partner, Fairmount Funds Management LLC · Since at least Jul 6, 2020); Dianthus Therapeutics, Inc. (Director · Sep 11, 2023 – Jan 22, 2024 · Past); Viridian Therapeutics, Inc. (Director · Oct 27, 2020 – Jun 26, 2024 · Past)
Chair of Board · Since at least Jun 13, 2025
Tomas Kiselak
Other companies: Cyclerion Therapeutics, Inc. (Chairman · Since at least Apr 1, 2026); Jade Biosciences, Inc. (Director · Since at least Apr 28, 2025); Zenas BioPharma, Inc. (Director · Since at least Sep 12, 2024); Oruka Therapeutics, Inc. (Director · Since at least Aug 29, 2024); Apogee Therapeutics, Inc. (Director · Since at least Jul 13, 2023); Spyre Therapeutics, Inc. (Director · Since at least Jun 22, 2023); Viridian Therapeutics, Inc. (Director · Since at least Oct 27, 2020); Dianthus Therapeutics, Inc. (Director · Sep 11, 2023 – Sep 27, 2024 · Past)
Director · Since at least Jun 13, 2025
Mark Alan Goldberg
Other companies: Blueprint Medicines Corp (Director · Since at least Jun 25, 2015); Audentes Therapeutics Inc (Director · Dec 11, 2017 – Jan 15, 2020 · Past); aTyr Pharma, Inc. (Director · May 6, 2015 – May 9, 2017 · Past); Aceragen Inc. (Director · Jan 7, 2014 – Jun 23, 2022 · Past); ImmunoGen Inc (Director · Nov 8, 2011 – Feb 12, 2024 · Past); Synageva BioPharma Corp (EVP, Medical & Reg. Strategy · Nov 2, 2011 – Sep 19, 2014 · Past)
Director · Jul 8, 2014 – May 1, 2024 · Past
Jonathan Violin
Other companies: Cyclerion Therapeutics, Inc. (Chief Executive Officer · Since at least Apr 1, 2026); Dianthus Therapeutics, Inc. (Director · Since at least Sep 11, 2023); Astria Therapeutics Inc (Director · Since at least Jan 28, 2021); Viridian Therapeutics, Inc. (Chief Executive Officer, Director · Oct 27, 2020 – Feb 2, 2023 · Past); Trevena, Inc. (SVP-Scientific Affairs & IR · Jan 29, 2018 – Feb 28, 2018 · Past)
Director · Since at least Jun 13, 2025
Scott Thomas Jackson
Other companies: Mural Oncology plc (Director · Since at least Oct 31, 2023); Spero Therapeutics, Inc. (Director · Since at least Apr 16, 2020); MacroGenics, Inc. (Director · Since at least Jan 24, 2017); Celator Pharmaceuticals Inc (Chief Executive Officer, Director · Jan 14, 2013 – Jul 12, 2016 · Past)
Director · Nov 27, 2018 – May 1, 2024 · Past
Timothy R. Pearson
Other companies: Korro Bio, Inc. (Director · Since at least Nov 3, 2023); Ra Pharmaceuticals Inc (Director · Oct 25, 2016 – Apr 2, 2020 · Past); Tesaro Inc (Exec. VP, CFO · May 27, 2014 – Jan 22, 2019 · Past); Catalyst Health Solutions Inc (EVP & Chief Financial Officer · Aug 22, 2011 – Jul 2, 2012 · Past)
Director · Mar 31, 2014 – May 1, 2024 · Past
Joshua Brumm
Other companies: Dyne Therapeutics, Inc. (CEO & President, Director · Sep 16, 2020 – Mar 8, 2024 · Past); Kaleido Biosciences, Inc. (See Remarks · Feb 27, 2019 – Mar 4, 2019 · Past); Aravive Inc (COO and CFO · Nov 12, 2015 – Oct 19, 2017 · Past)
Chief Executive Officer · Since at least Jun 13, 2025
Michael A Henos
Other companies: Genoptix Inc (Director · Oct 29, 2007 – Feb 25, 2011 · Past); Atherogenics Inc (Director · Apr 26, 2006 – Oct 31, 2008 · Past); Inhibitex Inc (Director · Feb 1, 2006 – Feb 13, 2012 · Past)
Director · Jan 9, 2014 – Jul 15, 2015 · Past
All 40 people
PersonSeat
Patricia S Andrews
Other companies: Geron Corporation (Director · Since at least Mar 25, 2026); Oncolytics Biotech Inc. (Director · Since at least Jan 1, 2026); Incyte Corporation (Chief Commercial Officer · Oct 21, 2008 – Jan 19, 2012 · Past)
Director · Jun 9, 2017 – May 1, 2024 · Past
Susan Moran
Other companies: Tyra Biosciences, Inc. (Board member · Since at least May 7, 2024); BioAtla, Inc. (Director · Since at least Dec 15, 2020); RayzeBio, Inc. (CHIEF MEDICAL OFFICER · Sep 14, 2023 – Feb 26, 2024 · Past)
Director · Since at least Jun 13, 2025
Harout Semerjian
Other companies: Geron Corporation (President and Chief Executive Officer · Since at least Aug 7, 2025); Immunomedics Inc (President and CEO, Director · Apr 16, 2020 – Apr 16, 2020 · Past)
Chief Executive Officer, Director · Aug 6, 2021 – Jan 12, 2024 · Past
Helen M Thackray
Other companies: ImmunoGen Inc (Director · Sep 22, 2021 – Feb 12, 2024 · Past); BioCryst Pharmaceuticals, Inc. (Chief R&D Officer · Sep 20, 2019 – Mar 31, 2025 · Past)
SVP Clinical Development, CMO · Jan 9, 2014 – Jan 20, 2021 · Past
Rachel King
Other companies: Fulcrum Therapeutics, Inc. (Board Member · Since at least Nov 12, 2024); Novavax, Inc. (Director · Since at least Oct 31, 2018)
Director · Jan 7, 2016 – May 1, 2024 · Past
Richard William Scalzo
Other companies: Dyne Therapeutics, Inc. (SVP, Head of Finance & Admin. · Sep 16, 2020 – Mar 11, 2025 · Past); Kaleido Biosciences, Inc. (Principal Accounting Officer · Oct 11, 2019 – Oct 11, 2019 · Past)
Chief Financial Officer · Since at least Jun 13, 2025
Alexandra Balcom
Other companies: Nuvalent, Inc. (Chief Financial Officer · Since at least Jul 28, 2021)
Director · Since at least Jun 13, 2025
Chinmaya Rath
Other companies: Geron Corporation (Senior Vice President, Chief Business Officer · Since Jul 13, 2026)
SVP and Chief Business Officer · Jan 12, 2024 – Jan 12, 2024 · Past
Daniel M. Junius
Other companies: IDEXX Laboratories, Inc. (Director · Since at least Oct 30, 2023)
Director · Mar 29, 2024 – May 1, 2024 · Past
Jonathan McNeill
Other companies: Dyne Therapeutics, Inc. (Chief Business Officer · Sep 16, 2020 – Aug 19, 2024 · Past)
President and Chief Operating Officer · Since at least Jun 13, 2025
Ryan Lynch
Other companies: Concert Pharmaceuticals Inc (PAO · Jun 15, 2017 – Aug 15, 2019 · Past)
Senior Vice President, Finance and Chief Accounting Officer · Since at least Jun 13, 2025
Scott Koenig
Other companies: MacroGenics, Inc. (Director · Since at least Feb 8, 2024)
Director · May 1, 2024 – May 1, 2024 · Past
Alex BalcomUntil Sep 18, 2026 · Past
Amy ReillyChief Communications Officer · Since at least Nov 3, 2026
Barbara BisphamGeneral Counsel · Since at least Jun 13, 2025
Brian M HahnSVP Finance, CFO · Jan 9, 2014 – Jun 18, 2024 · Past
Bruce S JohnsonSVP & Chief Commercial Officer · Jan 12, 2024 – Jan 12, 2024 · Past
Chris DoughtyChief Business Officer · Since at least Nov 4, 2026
Christopher Grant DoughtyChief Business Officer · Since at least Jun 13, 2025
Edwin RockChief Medical Officer · Sep 2, 2022 – Jun 20, 2024 · Past
Ellie ImChief Medical Officer · Since at least Jun 22, 2026
Eric Jay FeldmanChief Medical Officer · Mar 1, 2021 – Mar 1, 2021 · Past
Jan PinkasChief Scientific Officer · Since at least Jul 7, 2025
Jenna PoistDirector, Corporate Communications · Since at least Nov 3, 2026
John J BaldwinDirector · Jan 9, 2014 – Jun 29, 2016 · Past
John L MagnaniSVP of Research, CSO · Jan 9, 2014 – Nov 11, 2022 · Past
Rick ScalzoChief Financial Officer · Since at least Jul 31, 2025
Tanya SenguptaExecutive Vice President, Chief of Strategy and Operations · Since at least Jul 31, 2025
Wenjie ChengSenior Vice President, Technical Operations · Since at least Nov 4, 2026
William M GustDirector · Jan 9, 2014 – Jan 15, 2014 · Past

Open People

Log in to ask 6ix AI your own questions about Crescent Biopharma, Inc.